Biotech & Diagnostics

The Diluent Under Suspicion: A Formulation-First Checklist for UK Immunoassay Troubleshooting

An immunoassay that loses signal, gains background or drifts between plates rarely announces the true cause. In many UK laboratories, the antibody is nominated as the culprit long before the diluent, blocker or conjugate has been examined. That instinct is understandable: antibodies are the expensive, biologically variable component, and their failure would explain a great deal. It is also a costly way to troubleshoot. Buffer chemistry can mimic antibody failure closely enough to survive a casual review, and a reagent lot can be quarantined for a fault that sits one step upstream in formulation or preparation.

Begin with the evidence trail, not the antibody

The first control is not a new antibody. It is a complete account of what changed. For each affected run, record the date, operator, instrument, plate lot, sample type, control results, reagent lot numbers and the working diluent batch. Include the water source and the date on which the buffer was prepared. In UK laboratories operating under ISO 15189, this information should already be retrievable, but troubleshooting often reveals that reagent genealogy is less complete than the quality system assumes. A formulation-first investigation depends on being able to compare like with like.

Before testing any hypothesis, confirm that the problem is reagent-side. Repeat the same sample on a fresh aliquot with a different operator and, where possible, a different instrument. If the result follows the sample, the issue may be sample-related. If it follows the plate or reagent lot, continue. If it follows the working buffer, stop blaming the antibody.

The usual confounders in the buffer line

Buffer pH is the most familiar suspect, but it is rarely measured at the point of use. A concentrated stock may be correct while the working dilution is not, particularly where manual preparation and volumetric glassware introduce small errors. pH shifts alter antibody binding and can also change the behaviour of blocking proteins and conjugates. Ionic strength has a similar capacity to mislead: low salt may increase non-specific binding, while high salt may reduce antigen-antibody association. The effect is not always dramatic, which is why it can be mistaken for a gradual loss of antibody activity.

Blockers and stabilisers introduce another layer. Bovine serum albumin, casein, gelatin and synthetic blockers are not interchangeable across assays, and a supplier change can alter background without any change in the antibody. Stabilisers such as sucrose, trehalose or glycerol may protect one conjugate and interfere with another. Preservatives can affect enzyme activity or streptavidin binding. Even the buffer species matters: phosphate, Tris and carbonate systems behave differently with particular detection chemistries and sample matrices.

Conjugation chemistry deserves separate attention. A conjugate can lose performance because of low incorporation, over-labelling, aggregation or free label, even when the parent antibody remains sound. These are formulation and process effects, not necessarily antibody failures. Where the assay uses biotin-streptavidin, check for biotin interference separately; where it uses magnetic particles, check for aggregation and settling.

A formulation-first decision tree

A practical sequence keeps the antibody constant while changing one variable at a time.

1. Reconfirm the baseline. Run a known positive, a known negative and a blank with the current working reagents. Repeat with a retained reference buffer from a previously acceptable batch. If the reference buffer restores performance, the antibody is unlikely to be the primary cause.

2. Measure the working diluent. Check pH and conductivity with calibrated meters at the temperature stated in the SOP. Do not rely on the pH of the stock. If the working buffer is outside specification, prepare a fresh batch from a different stock and repeat.

3. Isolate the blocker. Prepare a small panel with the current blocker, a blocker-free version and, if available, an alternative blocker at the same protein concentration. A change in background or signal that tracks the blocker points to formulation rather than binding.

4. Examine the stabiliser and preservative. Remove or substitute one component at a time. This is especially important when a supplier has changed a formulation without changing the product code, or when an in-house buffer has been prepared from a new lot of a raw material.

5. Review the conjugate. Check the degree of labelling, aggregation and free label where the laboratory has the capability. If not, request the supplier's batch documentation and compare it with the previous lot. A conjugate fault can look like antibody failure because the detection step is where the loss of signal becomes visible.

6. Quarantine and compare lots. Do not blend a doubtful lot with a good one. Use retained samples to compare old and new lots side by side, and ask the supplier for a certificate of analysis and, where appropriate, a retention sample. In the UK, reagent traceability across suppliers and distributors is part of routine lot control, not an optional extra.

7. Only then assess the antibody. If the formulation variables have been excluded, review immunoreactivity, specificity and lot history. A genuine antibody failure should be demonstrated, not inferred from a single poor run.

UK sourcing and lot-control considerations

UK laboratories often source antibodies and raw materials through a mix of UK-based suppliers, European distributors and direct imports. Each route brings its own lot-control questions. A product code may remain stable while the formulation, carrier protein or preservative changes. Procurement records should therefore capture the supplier, lot number, date of receipt and any formulation statement, not simply the catalogue number.

Under ISO 15189, reagent lot verification should be proportionate to risk and documented. For immunoassays, that means checking not only the antibody but also the working diluent, conjugate and blocker where these are prepared in-house. Water quality is part of the same system: a change in purification cartridge or a lapse in maintenance can alter ionic content and microbial load without appearing on a reagent list.

Where kits carry UKCA marking, the manufacturer's instructions remain the reference point, but laboratory preparation still introduces variables that the kit manufacturer cannot control. A formulation-first approach is therefore compatible with regulatory compliance rather than an alternative to it. It simply recognises that the assay's performance is the product of the whole reagent system.

When the antibody really is at fault

Formulation-first triage is not a refusal to accept antibody failure. It is a way of making that conclusion defensible. If a fresh reference buffer, a new blocker and a verified conjugate all fail to restore performance, and the antibody lot differs from the previous acceptable lot, the evidence points toward the antibody. At that stage, the supplier should receive a structured complaint with the relevant lot numbers, assay conditions and comparative results.

If the buffer was the cause, the corrective action belongs in the SOP, the raw-material specification and the change-control record. The antibody should be released from suspicion, and the next investigation should begin with the question that caused the problem: what changed in the formulation, and why did the quality system not catch it sooner?